This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
ASCO 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2019
ESMO 2019
Prostate Cancer
Kidney Cancer
Bladder Cancer
Testicular Cancer
ESMO 2019 Bladder Cancer
Viewing 1-20 of 31 articles
ESMO 2019: Invited Discussant: How Do the Results of IMvigor130 Change Things in Bladder Cancer?
ESMO 2019: Invited Discussant: IMvigor130: Phase III Study of Atezolizumab with or without Platinum-Based Chemotherapy in Previously Untreated Metastatic Urothelial Carcinoma
ESMO 2019: EV-103 Enfortumab Vedotin plus Pembrolizumab for Urothelial Carcinoma
ESMO 2019: Invited Discussant: Results of the IMVigor130 Study of Atezoluzumab as Monotherapy, or in Combination with Platinum Chemotherapy for Patients with Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: Immune Therapy in Combination with Targeted Therapy
ESMO 2019: IMvigor130: Efficacy and Safety of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + Platinum-based Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: IMvigor130: Efficacy and Safety from a Phase 3 Study of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy vs Placebo + PBC in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: IMvigor130: Efficacy and Safety from a Phase 3 Study of Atezolizumab as Monotherapy or Combined with Platinum-based Chemotherapy versus Chemotherapy alone in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma
ESMO 2019: The NABUCCO Study, Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer
ESMO 2019: Invited Discussant: (904PD, 905PD, 906PD) NABUCCO (mUC), FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab (mUC), and Adjuvant Sunitinib in Patients with High-Risk (RCC)
ESMO 2019: Immune Therapy in Combination with Chemotherapy
ESMO 2019: Single Agent Immune Therapy and Immune Combinations
ESMO 2019: Erdatitinib versus Available Therapies in Advanced Urothelial Cancer: A Matching Adjusted Indirect Comparison
ESMO 2019: Hyperphosphatemia Due to Erdafitinib and Anti-tumor Activity Among Patients with Advanced Urothelial Cancer
ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as a Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer - A Medical Oncologist's Perspective
ESMO 2019: Pre-Operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer - NABUCCO
ESMO 2019: FGFR3 Alteration as a Predictor of Non-Response to Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer
ESMO 2019: Multiple-cohort Analysis Investigating FGFR3 Alteration as A Predictor of Non-response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
ESMO 2019: Pre-operative Ipilimumab and Nivolumab in Locoregionally Advanced, Stage III, Urothelial Cancer (NABUCCO)
ESMO 2019: Invited Discussant for EV-103: Initial Results of Enfortumab Vedotin plus Pembro and of BISCAY, an Adaptive, Biomarker Directed Platform study in Metastatic Urothelial Cancer
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free